References
- Available at: http://alsuntangled.com/open.php?rid=162. Accessed August 14, 2017. (Archived by WebCite® at http://www.webcitation.org/6siwfyEic).
- Available at: https://www.elysiumhealth.com. Accessed August 14, 2017. (Archived by WebCite® at http://www.webcitation.org/6siwj5jMG).
- URL:https://www.elysiumhealth.com/basis. Accessed August 14, 2017. (Archived by WebCite® at http://www.webcitation.org/6siwmbO9Z).
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350:1208–15.
- Mccormack D, Mcfadden D. A review of pterostilbene antioxidant activity and disease modification. Oxidat Med Cell Longev. 2013;2013:575482.
- Smith E, Shaw P, DeVos K. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2017;30:S0304–S394.
- Paez-Colasante X, Figueroa-Romero C, Sakowski S, Goutman S, Feldman E. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol. 2015;11:266–79.
- Carri M, Valle C, Bozzo F, Cozzolino M. Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS. Front Cell Neurosci. 2015;9:4.
- Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.
- Harlan B, Pehar M, Sharma D, Beeson G, Beeson C, Vargas M. Enhancing NAD + salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1). J Biol Chem. 2016;291:10836–46.
- Tang B. Could sirtuin activities modify ALS onset and progression? Cell Mol Neurobiol. 2017;37:1147–60.
- Available at: https://nadirakinci.com/my-als-story/. Accessed August 24, 2017. (Archived by WebCite® at http://www.webcitation.org/6sxk5OvF6).
- Kapetanovic I, Muzzio M, Huang Z, Thompson T, McCormick D. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011;68:593–601.
- Bedlack R, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
- Available at: https://www.patientslikeme.com/treatments/show/29028-elysium-nicotinamide-riboside-side-effects-and-efficacy?brand=t. Accessed August 14, 2017. (Archived by WebCite® at http://www.webcitation.org/6sixVgeSZ).
- Available at: https://www.elysiumhealth.com/basis/in-depth. Accessed August 14, 2017. (Archived by WebCite® at http://www.webcitation.org/6sixlEc0l).
- Personal communication between Elysium and ALSUntangled. August 24, 2017.